Key takeaways
- A study published in Nature found that semaglutide extended median lifespan in old female mice by roughly 12 percent.
- Treatment began at 20 months of age – late life for a mouse – and continued for the rest of the animals' lives.
- Median lifespan in the treated group rose from 742 days to 834 days.
- The drug outperformed dietary restriction on memory and blood sugar measures, suggesting a mechanism not explained by eating less.
- This is a mouse result. It does not establish that semaglutide extends human lifespan, and researchers are not recommending it for that purpose.
What the study found
Researchers led by Danica Chen, professor of metabolic biology and nutrition at the University of California, Berkeley, gave semaglutide to female mice beginning at 20 months of age and continued treatment for the remainder of their lives. The paper, titled “Late-life semaglutide treatment slows ageing and extends lifespan in female mice,” was published in Nature.
Median lifespan in the treated animals rose from 742 days to 834 days, an increase of about 12 percent. The treatment also slowed multiple hallmarks of biological aging rather than simply extending survival, and the animals performed better on memory and blood sugar measures than mice on dietary restriction.
Semaglutide is the active compound in Wegovy and Ozempic. It is prescribed for type 2 diabetes and obesity, and is used to lower cardiovascular risk, slow kidney decline and treat fatty liver disease. Adding a longevity question to a medicine already in widespread use is why this particular mouse study attracted more attention than most.
The timing of treatment matters. The animals were already old when it began. Interventions that extend lifespan when started in youth are common in the literature and much less useful clinically, because no one can be treated from birth on the strength of a hypothesis. A late-life intervention is closer to how a human medicine would actually be used.
The calorie restriction problem
To understand why researchers find this interesting, it helps to know what they have been looking for.
Dietary restriction is the most reliably reproduced life-extending intervention in laboratory animals. It is also close to useless as a human strategy, because sustained severe restriction is difficult to maintain, carries its own risks, and is not something clinicians can responsibly prescribe to a general population.
For more than a decade, the field has therefore searched for a calorie restriction mimetic: a compound that reproduces the biological effects of eating less without requiring it. Several candidates have been proposed. None has clearly delivered.
The Nature result is notable because of a specific difference. Dietary restriction extends lifespan while the body defends itself by lowering energy expenditure – the metabolic slowdown familiar to anyone who has studied weight regulation. Semaglutide produced many of the same benefits without triggering that defensive response, which suggests the effect is not simply a downstream consequence of reduced food intake.
Chen, who has studied calorie restriction for two decades, framed the implication carefully: the differences point to the possibility that GLP-1 drugs engage a biological pathway independent of calorie restriction, and identifying that route is an important direction for future longevity research.
That framing – a possibility worth investigating rather than a conclusion – is the appropriate one, and it is the part most likely to be lost in coverage.
What the human evidence actually shows
There is some human data. It is thin, and it measures something different from lifespan.
A post-hoc analysis of a 32-week, double-blind, placebo-controlled phase 2b trial in adults with HIV-associated lipohypertrophy examined epigenetic aging markers in 45 participants receiving semaglutide and 39 receiving placebo. Published in Nature Communications, the analysis found decreases across several validated epigenetic clocks after adjustment for sex, body mass index and inflammation markers, with eleven organ-system clocks moving in a concordant direction, most prominently those for inflammation, brain and heart. One measure, an intrinsic capacity clock, was unchanged.
The authors describe this as the first clinical-trial evidence that semaglutide modulates validated epigenetic biomarkers of aging, and say it justifies further evaluation of GLP-1 receptor agonists for healthspan extension.
Several limits belong with that. It is a post-hoc analysis rather than a trial designed to answer this question. The sample is small. The population is specific and not representative of the general public. And epigenetic clocks are biomarkers whose relationship to actual lifespan remains an active research question rather than a settled one.
What exists, then, is a mouse lifespan result and a small human biomarker signal. That is a reasonable basis for running proper trials. It is not a basis for conclusions.
The trials that would answer this
Those trials are being organised.
The VITAL-H trial, led by UT Health San Antonio's Barshop Institute, will enrol 726 adults in their 60s and compare three FDA-approved medications – rapamycin, dapagliflozin and semaglutide – against placebo across four study arms, with a budget of $38 million.
The underlying premise, as one investigator put it, is that aging modifies a relatively small number of core biological mechanisms driving most diseases, so an intervention targeting those mechanisms could influence many outcomes at once.
Note what VITAL-H measures: healthspan, meaning years lived in good health, rather than lifespan. That is a deliberate and sensible choice. Lifespan trials in humans take decades and are effectively unfundable; healthspan endpoints are reachable within a study's lifetime. It also means that even a successful result will not directly answer the question this mouse study raises.
Where this belongs in the evidence
Longevity research produces a steady stream of headlines, and the difficulty for a reader is that very different grades of evidence get reported in similar language. It helps to know which rung a finding occupies.
| Evidence type | What it shows | Semaglutide status |
|---|---|---|
| Cell and tissue studies | A mechanism is plausible | Established for GLP-1 pathways |
| Animal lifespan studies | Survival extended in that species | Demonstrated in female mice, late-life treatment |
| Human biomarker studies | Proxy measures of aging shift | Small post-hoc analysis, specific population |
| Human healthspan trials | People stay healthier for longer | VITAL-H enrolling; no results |
| Human lifespan trials | People live longer | None exist; impractical to run |
The bottom row is the reason this field is difficult to report. A trial that measured human lifespan directly would take decades and cost more than any funder will commit, so no such evidence is likely to exist for any intervention in the foreseeable future. Every claim about drugs extending human life is therefore an inference from something further up the table.
That is not a reason to dismiss the work. It is a reason to be precise about what has and has not been shown, and to treat the gap between a mouse survival curve and a human outcome as the substantial distance it is.
What this does not mean
Some cautions are worth stating plainly, because they will be omitted elsewhere.
The study was conducted in female mice. Sex differences in longevity interventions are common in animal research, and a result in female animals does not automatically transfer to males, let alone to humans.
Mice are not small people. The history of aging research contains many compounds that extended rodent lifespan and did nothing comparable in humans. The translation rate from mouse longevity studies to human medicine is poor, and researchers in the field are the first to say so.
Semaglutide is a prescription medicine with recognised side effects, prescribed for specific conditions. Nothing in this study supports taking it to live longer, and no researcher involved has suggested otherwise. Anyone considering these medicines should be discussing that with a doctor in the context of the conditions they are approved to treat.
The honest summary is narrow and still interesting: in one well-conducted animal study, a widely used drug started in late life extended median survival and slowed several measures of biological aging, apparently through a route distinct from eating less. That is a real finding, and it is a reason to run the human trials rather than a substitute for them.
Sources
- Feng Y, Barthez M, Wang Y, et al. – Late-life semaglutide treatment slows ageing and extends lifespan in female mice, Nature (2026), via ScienceDaily: https://www.sciencedaily.com/releases/2026/09/260911214238.htm
- Scientific American – GLP-1 weight-loss medication could slow aging and extend lifespan: https://www.scientificamerican.com/article/glp-1-weight-loss-medication-could-slow-aging-and-extend-lifespan/
- Intelligent Living – Ozempic Aging Study Finds the Drug Slowed Aging in Older Mice: https://intelligentliving.co/ozempic-aging-study-slowed-older-mice
- Corley MJ, et al. – Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy, Nature Communications (2026): https://pubmed.ncbi.nlm.nih.gov/40791720/
- University of California San Diego via ScienceDaily – Popular weight-loss drugs Ozempic and Wegovy may slow biological aging: https://www.sciencedaily.com/releases/2026/07/260713084907.htm
- UT Health San Antonio – UT San Antonio to lead $38 million national trial testing drugs to extend healthspan: https://news.uthscsa.edu/ut-san-antonio-to-lead-38-million-national-trial-testing-drugs-to-extend-healthspan/
- Texas Public Radio – San Antonio's Barshop Institute to test three approved drugs for slowing aging: https://www.tpr.org/podcast/the-source/2026-03-17/san-antonios-barshop-institute-to-test-three-approved-drugs-for-slowing-aging
- Artiverse – Obesity Drug Funding Meets a New Longevity Question: https://www.artiverse.ca/obesity-drug-funding-meets-a-new-longevity-question/